ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 502

Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort

Cécile Gaujoux-Viala1, Laure Gossec2, Maxime Dougados3, Francis Guillemin4 and Bruno Fautrel5, 1EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 2Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, 3Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 4CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 5Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, Early Rheumatoid Arthritis, functional status and remission

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome could then be defined by the association of these 3 elements. An alternative definition of favorable outcome keeps only the last 2 criteria: function + structure.

Objective: To assess which variables at baseline are associated with sustained favorable outcome over 3 years in early arthritis (EA) in daily clinical practice

Methods: – Patients: from the French cohort of EA ESPOIR (at least 2 swollen joints for less than 6 months and suspicion of RA) fulfilling the new ACR-EULAR criteria for RA at baseline.

               – Outcome: favorable outcome was defined by a criterion representing good functional ability (HAQ ≤0.5 and HAQ deterioration ≤0.25) and a criterion representing structural damage (absence of progression of the Sharp score over 1 year) with or without remission according to the new criteria of ACR / EULAR. Patients with sustained favorable outcome (according to the two definitions, ie using 2 and 3 criteria) over 3 years were analyzed.

                – Analysis: multinomial and ordinal logistic regression were used to determine which variables at baseline were independently associated with sustained favorable outcome. Sensitivity analyses on different definition of ‘sustained’ favorable outcome (sum, continuity rewarded score [2]) and on the timing of the treatment’s introduction were performed.

Results:

643 patients were analyzed (mean age of patients 48±12 years; 78% were women; mean DAS28 5.4±1.2). In all, 97 patients presented sustained favorable outcome using 2 criteria (function+structure) at least at 2 time-points and 29, sustained favorable outcome using 3 criteria. (function+structure+remission).  In the logistic regression models, only low HAQ and morning stiffness were always associated with sustained favorable outcome whatever the definition used (3 or 2 criteria). Being younger, living with a partner (being married/in a common-law relationship) and biological treatment during the first 6 months were associated with sustained favorable outcome using the 3 criteria (including remission). Being male, low Sharp score and no synthetic DMARD during the first year were associated with sustained favorable outcome using the 2 criteria (function+structure) (Table). To note the introduction of biological treatment after 6 months was not associated with sustained favorable outcome.

Variable at  J0

OR [95%CI] Sustained favorable outcome structure+function+remission

OR [95%CI] Sustained favorable outcome structure+function

Low age

1.17 [1.07;1.28]

NS

Low TJC

1.24 [1.01;1.54]

NS

Living with a partner

16.67 [1.04;250]

NS

Biological treatment during the first 6 months

28.6 [1.92;500]

NS

Low HAQ

31.25 [3.08;333.3]

2.38 [1.45;3.93]

Morning stiffness >1h

6.80 [1.46;31.2]

3.09 [1.99;4.78]

Low Sharp score

NS

 1.03 [1.005;1.06]

 Male

NS

1.70 [1.05;2.77]

No synthetic DMARD during the first year

NS

1.70 [1.06;2.72]

Conclusion: Early initiation of biological treatment is an important predictor of sustained favorable outcome (function+structure+remission) but not of sustained favorable outcome on structure and function only.

1.Felson DT et al. Ann Rheum Dis 2011; 70(3):404-13

2.Boers M, et al. J Clin Epidemiol. 2010 Jun;63:633-7


Disclosure:

C. Gaujoux-Viala,
None;

L. Gossec,
None;

M. Dougados,
None;

F. Guillemin,
None;

B. Fautrel,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-introduction-of-biologic-treatment-is-an-important-predictor-of-sustained-favorable-outcome-including-clinical-remission-in-early-arthritis-but-not-of-sustained-favorable-outcome-on-structure-an/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology